期刊简介
本杂志是由中华人民共和国卫生部主管，同济医科大学附属协和医院主办，国内外公开发行的学术性期刊，被国家科技部列为“中国科技论文统计源期刊”，被中国科学文献计量评价研究中心认定为《中国科学引文数据库》来源期刊。设有专家笔谈、临床研究、实验研究、研究报告、综述、进修苑、学术争鸣、经验介绍及病例报告等栏目。
往期目录
-
1999
-
2000
-
2001
-
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
首页>临床血液学杂志
- 杂志名称：临床血液学杂志
- 主管单位：中华人民共和国教育部
- 主办单位：华中科技大学同济医学院附属协和医院 北京大学医学院血研所
- 国际刊号：1004-2806
- 国内刊号：42-1284/R
- 出版周期：双月刊
期刊荣誉：中国核心期刊数据库收录期刊期刊收录：国家图书馆馆藏, 万方收录(中), 上海图书馆馆藏, CA 化学文摘(美), 统计源核心期刊(中国科技论文核心期刊), 知网收录(中), 维普收录(中)
组蛋白去乙酰化酶抑制剂治疗多发性骨髓瘤的新进展
郑焱华；徐莉；陈协群；高广勋
关键词：多发性骨髓瘤, 组蛋白去乙酰化酶抑制剂
摘要：Multiple myeloma (MM) is an incurable hematological malignancy characterized by clonal proliferation of plasma cclls within the bone marrow,resulting in anemia,osteolytic lesions,hypercalcemia,monoclonal immunoglobulin in the blood and/or urine, infection and renal impairment. Histone acetyltransferases and histone deacetylases (HDACs) are counteracting epigenetic enzymes regulating the status of protein acetylation thereby modulating gene transcription. Dysfunction of protein acetylation caused by aberrant expression of HDACs plays a critical role in tumor initiation and progression,thus making HDACs potential targets for cancer treatment. Specifically,combination treatment with HDACi (HDAC inhibitor) and proteasome inhibitors (bortezomib, carfilzomib) or immunomodulatory drugs (thalidomide, lenalidomide) shows synergistic anti-MM activity in both fundamental research and clinical trials. In this review, we summarize the recent research progress of HDACi in MM treatment and their mechanisms of anti-MM effect.
友情链接